SCHEMBL14697496

SCHEMBL14697496

[CH2]c1ccccc1-c1ccc(Br)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
MAPK1 P28482 3/20 0.50
PTPRC P08575 2/20 0.42
SLC6A3 Q01959 1/20 0.42
NPC1 O15118 6/20 0.41
RAB9A P51151 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
MAPT P10636 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 1/20 0.41
HSP90AA1 P07900 1/20 0.41
XBP1 P17861 1/20 0.41
MPI P34949 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TSHR P16473 2/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8416898 0.87 ALDH1A1 (0.38) ALDH1A1MAPK1PTPRCNPC1RAB9A
SCHEMBL19125933 0.82 ALDH1A1 (0.63) ALDH1A1MAPK1PTPRCSLC6A3NPC1
SCHEMBL7522172 0.82 ALDH1A1 (0.63) ALDH1A1MAPK1PTPRCSLC6A3NPC1
SCHEMBL95436 0.79 ALDH1A1 (0.48) ALDH1A1MAPK1TDP1HPGDCYP2A6
SCHEMBL27500515 0.79 ALDH1A1 (0.42) ALDH1A1MAPK1TDP1TSHRHPGD
SCHEMBL16954370 0.79 ALDH1A1 (0.34) ALDH1A1MAPK1PTPRCTDP1CYP2A6
SCHEMBL29410298 0.77 ALDH1A1 (0.74) ALDH1A1MAPK1PTPRCSLC6A3NPC1
SCHEMBL4825288 0.77 ALDH1A1 (0.74) ALDH1A1MAPK1PTPRCSLC6A3NPC1
SCHEMBL1481968 0.77 ALDH1A1 (0.46) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL27641143 0.77 ALDH1A1 (0.46) ALDH1A1MAPK1TDP1HPGDCYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9745288-B2 Compounds and methods for treating cancer by inhibiting the urokinase receptor INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2017-08-29 US claimed
US-20150051247-A1 COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2015-02-19 US claimed
WO-2013025939-A2 COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2013-02-21 WO claimed
CN-111491963-B Method for producing (meth) acrylic composition, coating material containing (meth) acrylic composition, and cured body 三菱瓦斯化学株式会社 2023-04-28 CN disclosed
CN-113710750-B (meth) acrylic composition, coating material containing same, and cured product 三菱瓦斯化学株式会社 2022-07-12 CN disclosed
US-20220145118-A1 (METH)ACRYLIC COMPOSITION, PAINT AND CURING AGENT COMPRISING SAME MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2022-05-12 US disclosed
US-11326073-B1 (meth)acrylic composition, paint and curing agent comprising same MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2022-05-10 US disclosed
CN-113710750-A (meth) acrylic composition, coating material containing same, and cured product 三菱瓦斯化学株式会社 2021-11-26 CN disclosed
CN-108603953-B Light diffusing agent, light diffusing resin composition, and molded article 三菱瓦斯化学株式会社 2021-08-24 CN disclosed
CN-109790366-B (meth) acrylic copolymer, resin composition, molded article thereof, and method for producing molded article 三菱瓦斯化学株式会社 2021-04-27 CN disclosed
CN-108822245-B (meth) acrylic acid-based copolymer 三菱瓦斯化学株式会社 2021-02-12 CN disclosed
CN-105705580-B (meth) acrylic copolymer, resin composition, and molded article thereof 三菱瓦斯化学株式会社 2018-07-20 CN disclosed
EP-3279259-A1 RESIN COMPOSITION AND MOLDED OBJECT OBTAINED THEREFROM Mitsubishi Gas Chemical Company, Inc. (JP) 2018-02-07 EP disclosed
CN-106459553-B Poly carbonate resin composition and its formed body 三菱瓦斯化学株式会社 2018-01-19 CN disclosed
US-20170327685-A1 RESIN COMPOSITION AND MOLDED OBJECT OBTAINED THEREFROM MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2017-11-16 US disclosed
US-9745288-B2 Compounds and methods for treating cancer by inhibiting the urokinase receptor INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2017-08-29 US disclosed
CN-106459553-A Polycarbonate resin composition and article molded therefrom 三菱瓦斯化学株式会社 2017-02-22 CN disclosed
CN-105705580-A (meth) acrylic copolymer, resin composition, and molded article thereof 三菱瓦斯化学株式会社 2016-06-22 CN disclosed
US-20150051247-A1 COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2015-02-19 US disclosed
WO-2013025939-A2 COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051247-A1 COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR PLAUR, PLAU, PLG ALDH1A1 1971/4885MAPK1 1646/4885PTPRC 790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.